A double blind, double-dummy, randomised, parallel groupmulticentre trial to compare the efficacy, tolerability, endometrial and bone effects of FASLODEX (fulvestrant) 250 mg monthly with NOLVADEX (tamoxifen) 20 mg daily when given as neoadjuvant treatment in post menopausal women with primary breast cancer

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].